Latest Conference Articles

Pamala A. Pawloski, PharmD, outlines barriers to precision medicine adoption at AMCP Nexus 2026, calling for standardization and education.

Experts at ASN Kidney Week say earlier detection, national CKD screening, and faster uptake are needed to bring new therapies to patients.

Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.

Five-year results from cohort A of CARTITUDE-2, presented at the International Myeloma Society Annual Meeting, show long, treatment-free remissions in lenalidomide-refractory patients who had 1 to 3 prior lines of therapy.

Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.

At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.

At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.

Adam Colborn, JD, discusses 340B reform, PBM policy, site-neutral payment, and other federal health policy issues to watch in 2027.

Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.

James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower treatment costs.

Jennifer S. Graff, PharmD, said payers need clearer standards to assess the reliability and credibility of patient experience data.

Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.

Data presented at ESMO Congress 2026 show lifileucel met its feasibility end point in refractory sarcoma, with 80% disease control among 10 patients.

Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.

Managed care organizations should start AI adoption with simple tools that build governance for future growth, Leanna Baker, PharmD, MS, said.

Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to costly oncology drugs.

Claims data also tied the combination to better adherence and fewer hospital admissions, including in bipolar I disorder, vs olanzapine alone.

At IDWeek 2026, clinicians explained how the meeting breaks down silos and keeps them ahead of what's next in infectious disease care.

Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings.

University of Virginia Health is tracking efgartigimod durability in generalized myasthenia gravis and how pharmacists help patients get past barriers.

Seven oncology leaders at PCOC in Nashville share what patient-centered care means today and how they want it to change over the next 5 years.

Clinicians at CHEST 2026 say costs and outcomes are shaped well beyond the ICU, from surgical choices to discharge planning and end-of-life talks.

Senu Apewokin, MD, explains why asymptomatic C diff carriage complicates care for transplant and chemotherapy patients excluded from trials.

Karolinska Institutet’s Antoine Créon, MD, explains how alert fatigue, workflow, and center-level variation may have limited a CKD alert trial.

Naima T. Joseph, MD, MPH, discusses why measles immunity screening in pregnancy is debated and how vaccination and counseling help.

Jordan Feld, MD, MPH, discusses bepirovirsen's approval and how capsid assembly modulators and gene editing could lead to a true hepatitis B cure.

Nevena Vicic, MSc, discusses first real-world data showing mRNA-1283 protected adults 65 and older from COVID-19 hospitalization in 2025-2026.

OneOncology's Larry Bilbrey outlines network-level contracting, data security, physician review of AI output, and clear vendor lanes for AI.